|
Dec 28
|
Top 15 Value Stocks to Buy for 2024
|
|
Dec 27
|
AbbVie (ABBV) Laps the Stock Market: Here's Why
|
|
Dec 27
|
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
|
|
Dec 27
|
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
|
|
Dec 26
|
AbbVie (NYSE:ABBV) Is Paying Out A Larger Dividend Than Last Year
|
|
Dec 26
|
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
|
|
Dec 24
|
Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly
|
|
Dec 22
|
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
|
|
Dec 22
|
14 Cheap DRIP Stocks To Buy Now
|
|
Dec 21
|
AbbVie (ABBV) Gains But Lags Market: What You Should Know
|
|
Dec 21
|
Better Growth Stock: AbbVie vs. Abbott Laboratories
|
|
Dec 20
|
Insiders At AbbVie Sold US$20m In Stock, Alluding To Potential Weakness
|
|
Dec 19
|
13 Most Promising Growth Stocks According to Analysts
|
|
Dec 19
|
10 Highest Dividend Stocks on Cash App
|
|
Dec 10
|
12 Healthcare Stocks Billionaires Like the Most
|
|
Dec 10
|
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December
|
|
Dec 10
|
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
|
|
Dec 9
|
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
|
|
Dec 9
|
3 Dividend Stocks You Can Safely Hold for Decades
|
|
Dec 9
|
Better Dividend Stock: AbbVie vs. Medical Properties Trust
|